Production Of Russia's COVID-19 Vaccine To Launch No Earlier Than Fall - Virologist
Muhammad Irfan Published July 13, 2020 | 05:20 PM
VLADIVOSTOK (UrduPoint News / Sputnik - 13th July, 2020) The industrial production of a coronavirus vaccine in Russia can be expected in the fall at the earliest, albeit forecasting a definite time frame is still premature, Sputnik has learned from Mikhail Schelkanov, the head of the microbe ecology lab at the school of Biomedicine of Russia's Far Eastern Federal University.
This past Sunday, Russia's Sechenov University announced that it had successfully completed clinical trials of a COVID-19 vaccine, developed by the Russia's Defense Ministry's Gamalei Institute of Epidemiology and Microbiology. Alexander Lukashev, the director of Sechenov's Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, told Sputnik that the trials had established the vaccine's safety on human health.
"This was only the first stage of trials � to test [the vaccine's] safety on human health. One has to understand that it is far from being the end of trials, those will continue. But it was encouraging and made it clear that Russia has the necessary technological potential," Schelkanov said.
According to the virologist, a biological preparation has to go a long way with several phases of trials before it can begin being industrially produced as a ready vaccine in quantities enough to cater for an entire population.
"The soonest we will launch the industrial production is in the fall, only if all phases of trials go perfectly well. But making forecasts is inappropriate. In biotechnology, it is a rare phenomenon for everything to go perfectly," Schelkanov said.
According to the World Health Organization's protocols, a vaccine has to go through three phases of studies to be approved for large-scale production.
Phase 1 is normally involves small-scale studies to determine a candidate vaccine's clinical tolerance and safety. Phase 2 then includes a larger number of subjects, with a focus on determining the optimal dose, intervals between doses and the minimum necessary number of doses of a candidate vaccine in a target population. Phase 3 trials are the largest in terms of number of subjects. A candidate vaccine is ready to move into industrial production if the last phase provides clear and definitive evidence of its safety and efficacy.
Recent Stories
Tennis: ATP Barcelona Open results - 1st update
Swiatek's perfect 10 in Stuttgart as Vondrousova stuns Sabalenka
Arandu's roads closed due to flooding
Oil tanker catches fire in Islamabad’s Blue Area
Pakistan committed to ensure safety of foreign nationals: FO
Tennis: WTA Stuttgart results - 1st update
Four passengers injured as train hit an empty vehicle
Over- speeding bus crushed to death two bike riders
Turkey's Freedom Flotilla ready to set sail for Gaza
French teen dies from heart failure after knife attack near school
Iranians appear unfazed by Isfahan blasts
UAF celebrates Int'l Chinese Language Day
More Stories From World
-
Togo lawmakers approve contested political reform
1 hour ago -
NATO must choose 'whether we indeed are allies': Zelensky
1 hour ago -
US House to vote on Ukraine, Israel, Taiwan aid package
1 hour ago -
Calls for calm after reported Israeli strike on Iran
2 hours ago -
IMF calls on EU to deepen single market integration to boost growth
2 hours ago -
Second Ecuadoran mayor killed ahead of anti-crime referendum: police
2 hours ago
-
Oil, gas drilling blocked in Alaska wilds as Biden seeks green cred
2 hours ago -
Man sets self on fire outside Trump trial
2 hours ago -
Turkey's Freedom Flotilla ready to set sail for Gaza
4 hours ago -
French teen dies from heart failure after knife attack near school
4 hours ago -
Iranians appear unfazed by Isfahan blasts
4 hours ago -
Ecuador mayor killed ahead of anti-crime referendum: police
4 hours ago